THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)

Lobbying for THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)

Filing 2nd Quarter - Report

2nd Quarter (Apr 1 - June 30) 2026 · District of Columbia · House · Senate · $2,120,000.00 expenses · posted Jul 20, 2026

Official filing document

Lobbying activity 5

Medicare/Medicaid

Issues related to prior authorization.

Pharmacy

Issues related to PBM and drug pricing reform, health care transparency and affordability. P.L. 119-75 Consolidated Appropriations Act, 2026. Issues related to the specialty drug market.

Defense

Issues related to Tricare pharmacy issues.

Health Issues

Issues related to employer sponsored health insurance. Issues related to the No Surprises Act.

Labor Issues/Antitrust/Workplace

Issues related to competition in the health care marketplace.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.